As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.

Drugmaker Novo Nordisk said the prescription medicine can be found at a range of pharmacies, including CVS and Costco, as well as some telehealth providers.

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include Ozempic and also drugs to treat asthma, breast cancer and leukemia.

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.

Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways to solve this problem.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries. 

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with pitfalls. Here's his tips for how to use them successfully.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients.

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.

The drug companies behind blockbuster weight loss and diabetes treatments have signaled that supply problems could soon be over, but many patients still have trouble getting the medicines. 

Several new studies find promising evidence that the GLP-1 class of drugs may have a cancer-preventive effect, especially for cancers linked to obesity.

Cheaper versions of Wegovy and Zepbound touted on social media could be fleeting. Copies are legal now because the brand-name drugs are in short supply. But the drugmakers are boosting production.

As more people try weight-loss drugs like Wegovy, some skip the brand name and buy compounded semaglutide from online pharmacies. But some of these may not follow state and federal standards.